HUP0004326A2 - A tumor-szupresszor génterápia és a kemoterápia kombinálása a daganatok kezelésében - Google Patents

A tumor-szupresszor génterápia és a kemoterápia kombinálása a daganatok kezelésében

Info

Publication number
HUP0004326A2
HUP0004326A2 HU0004326A HUP0004326A HUP0004326A2 HU P0004326 A2 HUP0004326 A2 HU P0004326A2 HU 0004326 A HU0004326 A HU 0004326A HU P0004326 A HUP0004326 A HU P0004326A HU P0004326 A2 HUP0004326 A2 HU P0004326A2
Authority
HU
Hungary
Prior art keywords
treatment
tumor suppressor
neoplasms
chemotherapy
gene therapy
Prior art date
Application number
HU0004326A
Other languages
English (en)
Inventor
G. William Demers
Jo Ann Horowitz
Daniel C. Maneval
Loretta Nielsen
Gene Resnick
Mary Ellen Rybak
Original Assignee
Canji Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc. filed Critical Canji Inc.
Publication of HUP0004326A2 publication Critical patent/HUP0004326A2/hu
Publication of HUP0004326A3 publication Critical patent/HUP0004326A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Electrotherapy Devices (AREA)

Abstract

A találmány tárgyát emlősrák- vagy hiperproliferatív sejtek kezeléséreszolgáló eljárás képezi, amelynek során az említett sejteket egytumorszuppresszor fehérjével vagy tumorszuppresszor nukleinsavval,továbbá legalább egy adjunktív rákellenes szerrel hozzák érintkezésbe.A jelen találmány tárgya továbbá egy olyan gyógyszerészeti készítményis, amely egy tumorszuppresszor fehérjét vagy tumorszuppresszornukleinsavat és legalább egy adjunktív rákellenes szert tartalmaz,valamint egy emlősrák- vagy hiperproliferatív sejtek kezeléséreszolgáló kit is. Ó
HU0004326A 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms HUP0004326A3 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US80176597A 1997-02-18 1997-02-18
US80175597A 1997-02-18 1997-02-18
US80128597A 1997-02-18 1997-02-18
US3806597P 1997-02-18 1997-02-18
US80168197A 1997-02-18 1997-02-18
US4783497P 1997-05-28 1997-05-28

Publications (2)

Publication Number Publication Date
HUP0004326A2 true HUP0004326A2 (hu) 2001-02-28
HUP0004326A3 HUP0004326A3 (en) 2003-07-28

Family

ID=27556335

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004326A HUP0004326A3 (en) 1997-02-18 1998-02-17 Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms

Country Status (19)

Country Link
EP (1) EP0969720B1 (hu)
JP (1) JP2001511815A (hu)
KR (2) KR100688409B1 (hu)
CN (1) CN1248731C (hu)
AT (1) ATE361668T1 (hu)
AU (1) AU737621B2 (hu)
BR (1) BR9807418A (hu)
CA (1) CA2282683A1 (hu)
CZ (1) CZ298488B6 (hu)
DE (1) DE69837754T2 (hu)
ES (1) ES2287974T3 (hu)
HK (1) HK1026579A1 (hu)
HU (1) HUP0004326A3 (hu)
IL (2) IL131447A0 (hu)
NO (1) NO993943L (hu)
NZ (1) NZ337283A (hu)
PL (1) PL193767B1 (hu)
SK (1) SK285969B6 (hu)
WO (1) WO1998035554A2 (hu)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
SK6598A3 (en) 1995-07-17 1998-09-09 Univ Texas P16 expression constructs and their application in cancer therapy
US7163925B1 (en) 1995-07-17 2007-01-16 Board Of Regents, The University Of Texas System p16 expression constructs and their application in cancer therapy
ES2383640T3 (es) 1996-11-20 2012-06-25 Crucell Holland B.V. Composiciones de adenovirus que pueden obtenerse mediante un método de producción y purificación mejorado
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
TW581763B (en) * 1997-12-22 2004-04-01 Schering Corp Combination and pharmaceutical composition comprising FPT inhibitor for treating proliferative diseases
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CA2325561A1 (en) * 1998-04-22 1999-10-28 Inex Pharmaceuticals Corporation Combination therapy using nucleic acids and conventional drugs
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
WO2000056351A2 (en) * 1999-03-19 2000-09-28 Schering Corporation Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
US6316462B1 (en) 1999-04-09 2001-11-13 Schering Corporation Methods of inducing cancer cell death and tumor regression
US6911200B2 (en) 2000-03-24 2005-06-28 Cell Genesys, Inc. Methods of treating neoplasia with combination of target-cell specific adenovirus, chemotherapy and radiation
US7048920B2 (en) 2000-03-24 2006-05-23 Cell Genesys, Inc. Recombinant oncolytic adenovirus for human melanoma
JP4564714B2 (ja) * 2000-11-27 2010-10-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 診断用腫瘍マーカー、腫瘍形成の阻害のための薬物スクリーニング、並びにがん治療用の組成物及び方法
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US7364727B2 (en) 2002-07-22 2008-04-29 Cell Genesys, Inc. Metastatic colon cancer specific promoter and uses thereof
WO2005082396A2 (en) 2003-12-01 2005-09-09 Introgen Therapeutics, Inc. Use of mda-7 to inhibit infection by pathogenic organisms
JPWO2005061007A1 (ja) * 2003-12-24 2007-07-12 学校法人 聖マリアンナ医科大学 癌の抑制方法
CA2551543A1 (en) * 2003-12-24 2005-07-07 Locomogene, Inc. Method of suppressing cancer
CA2586107A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. A novel method for the production and purification of adenoviral vectors
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
CN106692989A (zh) * 2017-03-07 2017-05-24 大连民族大学 一种药物脂质体/p53基因复合物及其制备方法和应用
CN109200295A (zh) * 2018-10-08 2019-01-15 蚌埠医学院 一种用于治疗卵巢癌的药物组合物及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
CA2173963C (en) * 1993-10-15 2002-03-19 W. Robert Bishop Tricyclic sulfonamide compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
KR100295224B1 (ko) * 1995-12-22 2001-09-17 둘락 노먼 씨. G-단백질기능의억제및증식성질환의치료에유용한트리사이클릭아미드

Also Published As

Publication number Publication date
CN1248731C (zh) 2006-04-05
PL193767B1 (pl) 2007-03-30
EP0969720A2 (en) 2000-01-12
NO993943D0 (no) 1999-08-17
CA2282683A1 (en) 1998-08-20
AU737621B2 (en) 2001-08-23
SK112299A3 (en) 2000-12-11
ATE361668T1 (de) 2007-06-15
DE69837754T2 (de) 2008-02-07
CN1252689A (zh) 2000-05-10
DE69837754D1 (de) 2007-06-21
NZ337283A (en) 2001-02-23
EP0969720A4 (en) 2004-05-12
KR100688409B1 (ko) 2007-03-02
HUP0004326A3 (en) 2003-07-28
AU6438098A (en) 1998-09-08
ES2287974T3 (es) 2007-12-16
EP0969720B1 (en) 2007-05-09
IL131447A0 (en) 2001-01-28
JP2001511815A (ja) 2001-08-14
CZ298488B6 (cs) 2007-10-17
KR20000071185A (ko) 2000-11-25
BR9807418A (pt) 2002-01-22
CZ293399A3 (cs) 2000-03-15
KR100620939B1 (ko) 2006-09-06
WO1998035554A2 (en) 1998-08-20
IL195605A0 (en) 2011-08-01
SK285969B6 (sk) 2007-12-06
PL335334A1 (en) 2000-04-25
NO993943L (no) 1999-10-15
WO1998035554A3 (en) 1998-11-26
HK1026579A1 (en) 2000-12-22
KR20050113287A (ko) 2005-12-01

Similar Documents

Publication Publication Date Title
HUP0004326A2 (hu) A tumor-szupresszor génterápia és a kemoterápia kombinálása a daganatok kezelésében
HUP0203968A2 (hu) Készítmények és eljárások prosztatarák terápiájára és diagnózisára
FI973467A (fi) DNA-molekyylejä, valmistus ja käyttö geeniterapiassa
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
HUP0203035A2 (hu) Prosztatarák terápiájára és diagnózisára alkalmas vegyületek és eljárások
TR199902053T2 (xx) Prostat kanserinin immunoterapisine y�nelik bile�ikler ve bunlar�n kullan�lmas�na matuf metodlar.
HUP0002038A2 (hu) Génszekvenálási eszközök és eljárások
WO2003004989A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
PT1157041E (pt) Anticorpos para terapia e diagnostico de cancro
ZA200108258B (en) Methods of inducing cancer cell death and tumor regression.
WO2004000094A8 (en) Predictive markers in cancer therapy
EP1004022A4 (en) METHODS AND COMPOSITIONS FOR OVERCOMING RESISTANCE TO BIOLOGICAL THERAPY AND CHEMOTHERAPY
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
WO1998059040A3 (de) Humane katalytische telomerase-untereinheit und deren diagnostische und therapeutische verwendung
TR199802648A3 (tr) Gen tedavisi için nüklein asit yapilari.
AU7614696A (en) Integrin-linked kinase, its inhibitors and methods of medical treatment using these inhibitors, gene therapy and pseudo-substrate inhibitors
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
WO2004047757A3 (en) Diagnosing and treating hematopoietic cancers
WO2003026494A3 (en) Galectins-1-and-4 in tumor development
HUP9902320A2 (hu) Enzimkombinációk osztódásban levő sejtek elpusztítására
AU1774299A (en) Polymorphisms within the rsk-3 gene related to cancer and methods of diagnosis, prognosis, and treatment
WO2000058464A3 (en) Rab genes and their uses
WO2000056351A3 (en) Combination use of gemcitabine and tumor suppressor gene therapy in the treatment of neoplasms
AU5778399A (en) Gene therapy for treatment of cancer

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees